KPI data tables

Novavax operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Novavax Cash, Marketable Securities, and Restricted Cash (USD millions)
PeriodCash + marketable securities + restricted cash
Q3 2026627
Q2 2026723.9
Q1 2026794.9
Q4 2025750.5
Q3 2025778.2
Q2 2025627.5
Q1 2025746.6
Q4 2024938.2

Source: Novavax selected consolidated balance sheet data in quarterly earnings releases and 10-K/10-Q liquidity notes. Cash equals cash and cash equivalents plus marketable securities plus restricted cash (thousands divided by 1,000). Q4 2024 and Q4 2025: FY 2025 Form 10-K (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm) $938.2 million and $750.5 million. Q1 2025 Exhibit 99.1 (https://ir.novavax.com/press-releases/2025-05-08-Novavax-Reports-First-Quarter-2025-Financial-Results-and-Operational-Highlights): $263,338 / $468,141 / $15,142. Q2 2025 Exhibit 99.1 (https://ir.novavax.com/press-releases/2025-08-06-Novavax-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights): $253,744 / $358,560 / $15,238. Q3 2025 Exhibit 99.1 (https://ir.novavax.com/press-releases/2025-11-06-Novavax-Reports-Third-Quarter-2025-Financial-Results-and-Operational-Highlights): $268,023 / $494,871 / $15,334. Q1 2026 Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvaxq1-26earningspressrele.htm): $228,363 / $561,969 / $4,562. Q2 2026 Exhibit 99.1 (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/prfinal.htm) and Form 10-Q (accession 0001000694-26-000018): $191,458 / $527,882 / $4,582. Q3 2026 Exhibit 99.1 filed 2026-11-05 (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000021/nvax3q26earningspressrelea.htm) and Form 10-Q (accession 0001000694-26-000022, https://www.sec.gov/Archives/edgar/data/1000694/000100069426000022/nvax-20260930.htm): $222,455 / $399,908 / $4,602. MidCap $330 million facility and $50 million initial draw: FY 2025 results release (26 Feb 2026) and Q1 2026 10-Q. $100 million unrestricted-cash covenant: FY 2025 10-K Credit Agreement discussion.

Novavax Deferred Revenue (APA Unwind) (USD millions)
PeriodDeferred revenue
Q3 2026432.2
Q2 2026443.3
Q1 2026448
Q4 2025499
Q3 2025501.4
Q2 2025513
Q1 2025517.9
Q4 20241,121.9
Q3 20241,128.8
Q2 20241,199.8
Q1 20241,082.4
Q4 2023863.5
Q3 2023801
Q2 2023907.4
Q1 2023689.8
Q4 2022549.6
Q3 20221,440.2
Q2 20221,516.1
Q1 20221,536
Q4 20211,595.5
Q4 2020273.2

Source: Novavax Form 10-Q and Form 10-K deferred-revenue / contract-liability balances, SEC XBRL us-gaap:ContractWithCustomerLiability (https://data.sec.gov/api/xbrl/companyconcept/CIK0001000694/us-gaap/ContractWithCustomerLiability.json). USD millions, later filing wins on restatement. Window Q4 2020–Q3 2026. Q1 2021–Q3 2021 omitted (no period-end tag). Canada APA $555.7 million current deferred revenue at December 31, 2024 and $575.7 million recognized as product sales in Q1 2025: FY 2025 10-K (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm). Q3 2026 deferred revenue $432.2 million (current $102.201 million plus non-current $330.011 million): Form 10-Q for September 30, 2026, filed 2026-11-05 (https://www.sec.gov/Archives/edgar/data/1000694/000100069426000022/nvax-20260930.htm). Remaining unsatisfied transaction price $0.5 billion of which $0.4 billion in deferred revenue at September 30, 2026: Q3 2026 10-Q (rounded, not plotted).

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Novavax (NVAX) - KPIs | Sterling